UbiQ develops and commercializes reagents based on ubiquitin and ubiquitin-like proteins. With these reagents we aim to enable and expedite fundamental research and drug discovery in the ubiquitin field.
UbiQ was founded by the late professor Huib Ovaa, Farid El Oualid and Alfred Nijkerk in 2010 as a spin-out of the Netherlands Cancer Institute (Amsterdam, The Netherlands).
Our products are targeted at pharma companies and academic research labs. Next to our reagent business, we also develop specific HTS assay reagents and conduct inhibitor screening programs, both for internal development as well as partnered with Pharma.
Ultimately, we envision UbiQ as a company with substantial cash flow from its reagent and assay business and with a strong project pipeline and major strategic partnerships with several of the world's leading pharma companies, driving a significant upside potential for our shareholders.
a brief pitch by Farid El Oualid (CSO).